Sonoma Pharmaceuticals Finalizes $4M Unit Offering at Deep Discount, Significant Dilution Confirmed

summarizeSummary

Sonoma Pharmaceuticals has finalized a $4 million public offering of units at $1.35 per unit, priced at a significant discount and resulting in massive dilution for existing shareholders to address critical liquidity needs.

check_boxKey Events

• Offering Finalized

  The company has finalized its public offering, selling 2,962,962 units at $1.35 per unit, raising approximately $4 million in gross proceeds. This finalizes the terms of the offering initiated on April 17, 2026.

• Significant Dilution

  The offering immediately increases outstanding common stock by over 160%. If all associated common warrants, pre-funded warrants, and underwriter's warrants are exercised, total potential dilution could exceed 350% relative to pre-offering shares.

• Discounted Pricing

  Units are priced at $1.35, representing a 25% discount to the $1.80 closing price on April 23, 2026, the day prior to the offering's pricing.

• Warrants Included

  Each unit includes one common warrant with an exercise price of $1.35, and pre-funded warrants are offered as an alternative, adding further potential dilution to the share count.

auto_awesomeAnalysis

This 424B4 filing finalizes the terms of Sonoma Pharmaceuticals' public offering, which was previously announced via S-1 and S-1/A filings. The company will raise approximately $4 million by selling units at $1.35 each. This pricing represents a 25% discount to the $1.80 closing price on April 23, 2026, immediately prior to the offering's pricing. The offering is highly dilutive, immediately increasing outstanding shares by over 160% and potentially by over 350% if all associated warrants are exercised. While this capital infusion is critical for a company facing a going concern warning and significant cash burn, the deeply discounted terms and substantial dilution reflect financial distress and will severely impact existing shareholders.